Skip to main content
TipRanks
Go Ultimate75% OFF

Journey Medical Corp (DERM) Q3 2026 Earnings Report

122 Followers

DERM Q3 2026 EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.02
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$0.09

DERM Q3 2026 Revenue Results

Actual Revenue
$18.97M
Expected Revenue
$20.32M
Beat/Miss
Missed by -$1.35M
YoY Revenue Growth
+7.58%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
DERM Upcoming Earnings

Journey Medical Corp's next earnings date is estimated for March 31, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DERM Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-11.16%|
Earnings Call Sentiment|Positive

The call was predominantly positive, marked by revenue and net product sales growth, improving gross margin, two consecutive quarters of positive EBITDA, strong Emrosi prescription and prescriber expansion, favorable refill trends, compelling clinical data, and expected payer-access improvements. The company still reported a GAAP loss, a lower cash balance, one-time vendor settlement costs, temporary prescription volatility following a copay change, and incomplete formulary coverage, but management characterized these issues as manageable or nonrecurring while emphasizing continued commercial momentum.

Company Guidance

Management expects Emrosi’s key metrics to “continue to trend positively in the coming quarters,” ASP to “trend higher in the coming quarters,” and high-quality coverage to increase from “40% of commercial lives,” or about “170 million, 180 million lives,” after a large national plan covering “over 25 million lives” takes effect at the beginning of 2027; quality coverage means “a single-step or better.” Management expects the plan’s impact to be felt “beginning in Q1,” anticipates an “upward trend on ASP and improvement in gross-to-net as the quarters progress in '27,” expects newly added representatives to have “a good 2 quarters” to become productive, and said prescription volatility after the copay change might take “anywhere from 4 to 8 weeks” to recover. SG&A is expected to be “consistent or a little bit lower as a percentage of revenue,” while management is “probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance” on 2027 revenue or EBITDA.

  • Revenue Growth and Improved ProfitabilityThird-quarter total revenue was $19 million versus $15 million in the third quarter of 2025, with management reporting 8% year-over-year growth. Net product sales increased 11% year-over-year, gross margin improved to 69% from 67%, and the company achieved positive EBITDA for the second consecutive quarter.
  • Emrosi Revenue and Prescription GrowthEmrosi generated $9 million in net revenue during the third quarter, increasing both year-over-year and sequentially. Prescriptions reached approximately 40,000, up from about 36,000 in the second quarter, representing approximately 8% sequential quarterly growth.
  • Expansion of Emrosi Prescriber BaseUnique Emrosi prescription writers increased by approximately 500 during the quarter to more than 5,000, reaching the company's internal goal for the year. Management said the prescriber base continues to grow and noted that there are over 14,000 dermatologists in the United States.
  • Strong Refill Demand and Patient SatisfactionEmrosi growth continued to be driven by strong refill demand and the ramp in prescribers. Refill rates increased nearly 12% from the second quarter to the third quarter, which management cited as an indication of high patient satisfaction.
  • Emrosi Clinical Efficacy AdvantagePost-hoc Phase III data showed that nearly 50% of patients who achieved the primary Investigator Global Assessment success endpoint had complete resolution of rosacea symptoms at the end of treatment. Nearly 30% of mild-to-moderate rosacea patients achieved clear skin with Emrosi, compared with 12.8% for Oracea, or more than 2.5 times as many patients achieving clear skin.
  • Durable Safety Profile and Product DifferentiationManagement said Emrosi's placebo-like safety and tolerability profile remains durable. Rapid onset of action, superior skin-clearing effects, and head-to-head efficacy data versus Oracea were described as important factors supporting adoption among dermatology providers.
  • Commercial Expansion and Marketing InitiativesThe company added 5 new sales territories, increased its sales force from 35 to about 40 representatives, continued peer-to-peer marketing and conference activity, and sponsored a poster at the 26th Annual Fall Clinical Dermatology Conference highlighting Emrosi clinical data. Management is also planning additional journal publications and is considering a second switching trial in 2027.
  • Progress in Payer CoverageThe calculated average selling price for Emrosi has increased each quarter since the beginning of the year as reimbursed prescriptions become a larger part of the business mix. The company completed agreements with all of the top 3 GPOs in the nation, reached 40% high-quality access among commercial lives, and had a large national health plan add Emrosi to its formulary in early August.
  • Expected 2027 National Formulary CatalystManagement expects the largest national plan in the United States to add Emrosi at the beginning of 2027. The plan covers more than 25 million lives, and the company expects the adoption to increase the proportion of prescriptions processed as covered rather than through the bridging program.
  • Narrowed GAAP Loss and Positive Adjusted EBITDAGAAP net loss narrowed to $1.3 million, or $0.05 per basic and diluted share, from a $3.9 million loss, or $0.14 per share, in the third quarter of 2025. Adjusted EBITDA reflected net income of $3.5 million versus $1.4 million in the prior-year quarter.
  • Operating Leverage and Continued InvestmentManagement said net product sales grew significantly faster than expenses and that the company remains on a path toward becoming sustainably earnings and cash-flow positive. SG&A is expected to remain consistent or decline slightly as a percentage of revenue while the company continues investing in Emrosi, its sales force, market access programs, and its broader dermatology portfolio.
  • Business Development OpportunitiesJourney Medical continues to explore out-licensing opportunities for commercial rights to its patented products in non-U.S. territories and potential in-licensing opportunities to expand its dermatology product offering and increase value for the company.

DERM Earnings History

DERM earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 31, 20272026 (Q4)-0.03--0.04――
Nov 12, 20262026 (Q3)-0.02-0.05-0.0944.44% (+0.04)
Aug 12, 20262026 (Q2)-0.02-0.01-0.1693.75% (+0.15)
May 13, 20262026 (Q1)-0.09-0.08-0.1855.56% (+0.10)
Mar 25, 20262025 (Q4)-0.05-0.040.1-140.00% (-0.14)
Nov 12, 20252025 (Q3)-0.05-0.09-0.1225.00% (+0.03)
Aug 12, 20252025 (Q2)-0.10-0.16-0.175.88% (+0.01)
May 14, 20252025 (Q1)-0.24-0.18-0.5366.04% (+0.35)
Mar 26, 20252024 (Q4)-0.200.10-0.59116.95% (+0.69)
Nov 12, 20242024 (Q3)-0.17-0.120.99-112.12% (-1.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed